AstraZeneca: Calquence drug meets goal in leukaemia study
(CercleFinance.com) - AstraZeneca said its leukaemia drug Calquence has met the primary endpoint in a Phase III trial in previously-treated patients with chronic lymphocytic leukaemia, the most common type of leukaemia in adults.
Results showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Calquence monotherapy compared to treatment based on Roche's rituximab, the Anglo-Swedish drugmaker said.
Calquence was granted accelerated approval by the US Food and Drug Administration in October 2017 for the treatment of adult patients with mantle cell lymphoma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Results showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Calquence monotherapy compared to treatment based on Roche's rituximab, the Anglo-Swedish drugmaker said.
Calquence was granted accelerated approval by the US Food and Drug Administration in October 2017 for the treatment of adult patients with mantle cell lymphoma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.